* If you want to update the article please login/register
Pitavastatin, Albeit's well-known anti-hyperlipidemic drug, has been reported to have other medical uses. Both in vitro and in vivo in an Ehrlich ascites carcinoma cell line; this effect has been investigated in this study for the first time via its oral delivery packed in bilosomes; HepG2 and in vivo in an Ehrlich ascites carcinoma model. In addition, the effects of surface modification of bilosomes with lactoferrin as an important target ligand for HCC was investigated. To optimize the bilosomal formulation, thin-film hydration and different molar phospholipid to bile salt ratios were used. At pH 7. 4 the molar phospholipid to bile salt ratio was adjusted to 4:1. When tested on Caco-2 cells by 3. 1 folds, LF-coated bilosomes also increased permeation of PIT. According to a RT-PCR review, LF-coated PIT-loaded bilosomes contributed to an increase in PIT's apoptotic sensitivity caused by caspase-3.
Source link: https://europepmc.org/article/MED/36081339
With IC 50 values from 0. 62 to 1. 69 bcM, HepG2, Sk-Hep-1, and Huh-7 cells, which were much larger to berberine, was the most active against three human hepatoma cells, including HepG2, Sk-Hep-1 and Huh-7 cells, which were much superior to berberine. 6k was shown to have reduced cytotoxicity against normal hepatocytes L-02 with good lipid-water partition properties, but more significantly, 6k had reduced cytotoxicity against normal hepatocytes L-02 with elevated lipid-water partition properties. In the H22 liver cancer xenograft mouse model, the in vivo anti-HCC activity of 6k was established.
Source link: https://europepmc.org/article/MED/36065941
Although intraperitoneal administration of chemotherapy drugs is routinely used to treat cancerous ascites, conventional medications have poor retention and therefore must be administered frequently to maintain a stable anti-tumor effect. In a mouse model of advanced HCC with ascites, tumor cell proliferation and micro-angiogenesis were greatly reduced, which led to apoptosis in the H22 cells in vitro, ascites formation, tumor cell proliferation and micro-angiogenesis was significantly reduced.
Source link: https://europepmc.org/article/MED/35975331
Context Urolithin A can slow the proliferation of many human cancer cells, but it has not been reported if UroA restricts nasopharyngeal carcinoma cells. In vitro, the aim was to investigate UroA's inhibitory effect on NPC and a possible mechanism in vitro. Using RNA-sequencing-based mechanistic test, we made a prediction based on a randomized enrichment of 40 bcM UroA-treated CNE2 cells for 24 h. After NPC cells were treated with 20-60 u03bcM UroA, proliferation, migration, and invasion of were measured by colony formation, wound healing, and transwell experiments. UroA mostly modified the ECM receptor interaction pathway, according to RNA-sequencing and KEGG enrichment. In addition, co-treatment of UroA and NAC may reverse UroA's effect on apoptosis-related proteins. The behavior of drugs for tumor therapy can be investigated by RNA-sequencing techniques based on bioinformatic studies.
Source link: https://europepmc.org/article/MED/35952389
Enzyme-linked immunosorbent assay was used to determine serum IGFBP3 levels in the study cohort, which included 136 ESCC patients and 119 healthy controls, as well as the validation cohort with 55 ESCC patients and 42 normal controls. Serum IGFBP3 levels were markedly lower in early-stage ESCC or ESCC patients than those in normal controls. Generally, the sensitivity and sensitivity of serum IGFBP3 for the diagnosis of ESCC were 95. 80% and 50. 0 percent, respectively, with the training cohort being under the ROC curve at 0. 888. Importantly, serum IGFBP3 could also distinguish early-stage ESCC from controls. Independent cohort validation confirmed that IGFBP3 was the first diagnostic marker in oesophageal squamous cell carcinoma. In addition, serum IGFBP3 was found as a prognostic risk factor, and it was used to develop a nomogram with improved prognosis capability in oesophageal squamous cell carcinoma.
Source link: https://europepmc.org/article/MED/35930383
It's unclear if hepatitis B virus DNA is a risk factor for HCC recurrence after OLT. Patients with detectable HBV DNA were found to have higher AFP concentrations, greater incidence of macrovascular invasion, increased tumor diameter, poorer TNM stage, and a greater share of expanded OLT criteria and HCC recurrence compared to patients with HBV DNA undetectable. However, a risk factor for HCC-related death, according to the authors of urgent OLT, a greater percentage of extended OLT standards, and HCC-recurrence. HBV DNA > 2000 IU/mL was not a risk factor for long-term survival.
Source link: https://europepmc.org/article/MED/35930293
Exosome DNA can be used for liquid biopsy, which can be used for liquid biopsy. This was the first to use droplet digital PCR to identify tumor-specific mutations in exoDNA and to determine hepatocellular carcinoma patients' prognosis. The TP53 gene was found to have a c. 747 G > T mutation in the TP53 gene by ddPCR. To determine the connection between mutation frequency and prognostic, we used Cox regression to determine the relationship. In exoDNA, 48 of 60 patients had a c. 747 G > T mutation in the TP53 gene in exoDNA, according to the scientists. The corresponding AUC was 0. 761, according to the ROC curve analysis, the highest cutoff value for mutation frequency prediction to MVI was 67%. Patients with low-frequency mutation deterioration continued median recurrence-free survival for 63 days, down from 368 days for patients with low-frequency mutation. We have evidence that exoDNA mutations can be used to identify patients with poor RFS.
Source link: https://europepmc.org/article/MED/35921289
fatty acid binding protein 5 is commonly elevated in several human malignancies, according to Mounting evidence. However, the mechanisms underlying FABP5's involvement in hepatocellular carcinoma remain unclear. In addition, FABP5 promoted HCC cell formation, migration, and invasion. FABP5, according to Mechanistic's report, may have increased cAMP-response element binding protein phosphorylation. In the meantime, CREB, as a transcription factor, upregulated the miR-889-5p expression by attaching to the miR-889-5p promoter region. A FABP5/CREB/miR-889-5p/KLF9 axis for HCC progression has been established, and we note that blocking this vital signaling pathway may be a promising treatment option for HCC treatment.
Source link: https://europepmc.org/article/MED/35816613
We extracted gold nanoparticles from Pseudobulbus Cremastrae Seu Pleiones' extract to broaden the use of nanobiotechnology by a fast and green process. Ultrasynthesized Au nanoparticles containing PCSP were characterized by UV-vis microscopy, transmission electron microscopy, dynamic light scattering, Fourier transform infrared spectroscopy, and Energy Dispersive X-ray. Specifically, we investigated the direct in vitro effects of PCSP-AuNPs on hepatocellular carcinomas. Using a mouse model with H22-tumor, we investigated the immune system of PCSP-AuNPs, splenic lymphocyte proliferation, cytokines levels, and the CD4+/CD8+ cell ratio in the peripheral blood. PCSP-AuNPs not only contained low toxicity, but also enhanced the immune-mediated antitumor response when compared to PCSP alone, suggesting its potential as a novel and effective treatment for liver cancer therapy.
Source link: https://europepmc.org/article/MED/35762637
Purpose Skeletal muscle index is a good predictor of medical outcomes in patients with malignant illnesses. To determine if changes in the PMI predicted OS in people with HCC treated with TACE, it will be determined if there are any changes in the PMI predicted OS. Patients and methods Using retrospective analysis was done in HCC patients treated with TACE between January 2018 and March 2019. Patients with low PMI were less likely in patients with low PMI than those with higher PMI. According to a multivariate review, either PMI or SMI was significantly related to OS. Conclusion: PMI is a simple way to estimate OS in HCC patients treated with TACE. Low psoas-muscle index has been attributed to reduced overall survival in hepatocellular carcinoma treated with transarterial chemoembolization, which has made it more possible to obtain widespread clinical use.
Source link: https://europepmc.org/article/MED/35639492
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions